• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein

by Adam | Oct 22, 2016

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein Scios Inc, Brown University, Amgen Clinical Immunology (2007). [ISPRI prediction of immunogenicity]
HIV vaccine development by computer assisted design: the GAIA vaccine

HIV vaccine development by computer assisted design: the GAIA vaccine

by Adam | Oct 22, 2016

Vaccine. 2005 Mar 18; 23 [7-18):2136-48.
Developing an epitope-driven tuberculosis (TB) vaccine

Developing an epitope-driven tuberculosis (TB) vaccine

by Adam | Oct 22, 2016

Vaccine. 2005 Mar 18; 23(17-18):2121-31.
Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island

Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island

by Adam | Oct 22, 2016

Human Vaccines 2006 June; 2(3), 119-128.
Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

by Adam | Oct 22, 2016

Vaccine. 2007 Apr 20;25(16):3179-91.

Recent Posts

  • EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
  • EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction 
  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy. 

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}